Correction to Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modulator Fingolimod at Low Doses in Ulcerative Colitis Preclinical Models

Abstract Background Muscle stem cells (MuSCs) are absolutely required for the formation, repair, and regeneration of skeletal muscle tissue. Increasing evidence demonstrated that tissue stem cells, especially mesenchymal stem cells (MSCs), can exert therapeutic effects on various degenerative and inflammatory disorders based on their immunoregulatory properties. Human mesenchymal stem cells (hMSCs) treated with interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) were reported to possess anti-inflammatory functions by producing TNF-stimulated gene 6 (TSG-6). However, whether human muscle stem cells (hMuSCs) also possess TSG-6 mediated anti-inflammatory functions has not been explored. Methods The ulcerative colitis mouse model was established by subjecting mice to dextran sulfate sodium (DSS) in drinking water for 7 days. hMuSCs were pretreated with IFN-γ and TNF-α for 48 h and were then transplanted intravenously at day 2 of DSS administration. Body weights were monitored daily. Indoleamine 2,3-dioxygenase (IDO) and TSG-6 in hMuSCs were knocked down with short hairpin RNA (shRNA) and small interfering RNA (siRNA), respectively. Colon tissues were collected for length measurement and histopathological examination. The serum level of IL-6 in mice was measured by enzyme-linked immunosorbent assay (ELISA). Real-time PCR and Western blot analysis were performed to evaluate gene expression. Results hMuSCs treated with inflammatory factors significantly ameliorated inflammatory bowel disease (IBD) symptoms. IDO and TSG-6 were greatly upregulated and required for the beneficial effects of hMuSCs on IBD. Mechanistically, the tryptophan metabolites, kynurenine (KYN) or kynurenic acid (KYNA) produced by IDO, augmented the expression of TSG-6 through activating their common receptor aryl hydrocarbon receptor (AHR). Conclusion Inflammatory cytokines-treated hMuSCs can alleviate DSS-induced colitis through IDO-mediated TSG-6 production.

Download Full-text

Effect of a Milk-Based Fruit Beverage Enriched with Plant Sterols and/or Galactooligosaccharides in a Murine Chronic Colitis Model

Foods ◽

10.3390/foods8040114 ◽

2019 ◽

Vol 8 (4) ◽

pp. 114 ◽

Cited By ~ 2

Author(s):

Gabriel López-García ◽

Antonio Cilla ◽

Reyes Barberá ◽

Amparo Alegría ◽

María Recio

Keyword(s):

Ulcerative Colitis ◽

Experimental Colitis ◽

Plant Sterols ◽

Mice Model ◽

Colon Tissue ◽

Clinical Model ◽

Need To Evaluate ◽

Anti Inflammatory ◽

Enriched Milk ◽

Inflammatory Effect

The potential anti-inflammatory effect of plant sterols (PS) enriched milk-based fruit beverages (PS, 1 g/100 mL) (MfB) with/without galactooligosaccharides (GOS, 2 g/100 mL) (MfB-G) in an experimental mice model of chronic ulcerative colitis was evaluated. Beverages were orally administered to mice every day by gavage to achieve PS and GOS doses of 35 and 90 mg/kg, respectively, and experimental colitis was induced by giving mice drinking water ad libitum containing 2% (w/v) dextran sulphate sodium (DSS) for 7 days, alternating with periods without DSS up to the end of the study (56 days). MfB beverage showed significant reduction of symptoms associated to ulcerative colitis and improved the colon shortening and mucosal colonic damage, but it was not able to reduce the increase of myeloperoxidase levels produced by DSS. MfB-G showed higher incidence of bloody feces and loss of stool consistency than MfB, as well as high levels of immune cells infiltration in colon tissue and myeloperoxidase. Therefore, PS-enriched milk-based fruit beverage could be an interesting healthy food to extend the remission periods of the diseases and the need to evaluate, in a pre-clinical model, the anti-inflammatory effect of the combination of bioactive compounds in the context of a whole food matrix.

Download Full-text

Salmon diet in patients with active ulcerative colitis reduced the simple clinical colitis activity index and increased the anti-inflammatory fatty acid index – a pilot study

Scandinavian Journal of Clinical and Laboratory Investigation ◽

10.3109/00365513.2010.542484 ◽

2010 ◽

Vol 71 (1) ◽

pp. 68-73 ◽

Cited By ~ 20

Author(s):

Tore Grimstad ◽

Rolf K. Berge ◽

Pavol Bohov ◽

Jon Skorve ◽

Lasse Gøransson ◽

...

Keyword(s):

Ulcerative Colitis ◽

Fatty Acid ◽

Pilot Study ◽

Activity Index ◽

Active Ulcerative Colitis ◽

Anti Inflammatory ◽

Acid Index ◽

Salmon Diet

Download Full-text

Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist

Gastroenterology ◽

10.1016/0016-5085(94)90696-3 ◽

1994 ◽

Vol 106 (3) ◽

pp. 637-642 ◽

Cited By ~ 287

Author(s):

John C. Mansfield ◽

Hazel Holden ◽

Joanna K. Tarlow ◽

Francesco S. Di Giovine ◽

Tarra L. McDowell ◽

...

Keyword(s):

Ulcerative Colitis ◽

Receptor Antagonist ◽

Genetic Association ◽

Inflammatory Cytokine ◽

Interleukin 1 ◽

Interleukin 1 Receptor Antagonist ◽

Anti Inflammatory ◽

Anti Inflammatory Cytokine

Download Full-text

P045 5-Aminosalicylates promote inflammation resolution in ulcerative colitis through generation of anti-inflammatory hydroxy fatty acids

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjx002.171 ◽

2017 ◽

Vol 11 (suppl_1) ◽

pp. S100-S101

Author(s):

R. Wysoczanski ◽

A. Kendall ◽

M. Motwani ◽

R. Vega ◽

F. Rahman ◽

...

Keyword(s):

Ulcerative Colitis ◽

Fatty Acids ◽

Hydroxy Fatty Acids ◽

Anti Inflammatory ◽

Inflammation Resolution

Download Full-text

Lactobacillus acidophilus and Clostridium butyricum ameliorate colitis in murine by strengthening the gut barrier function and decreasing inflammatory factors

Beneficial Microbes ◽

10.3920/bm2017.0035 ◽

2018 ◽

Vol 9 (5) ◽

pp. 775-787 ◽

Cited By ~ 3

Author(s):

Y. Wang ◽

Y. Gu ◽

K. Fang ◽

K. Mao ◽

J. Dou ◽

...

Keyword(s):

Ulcerative Colitis ◽

Lactobacillus Acidophilus ◽

Barrier Function ◽

Clostridium Butyricum ◽

In Vivo Studies ◽

Inflammatory Factors ◽

Sprague Dawley ◽

Trinitrobenzenesulfonic Acid ◽

Gut Barrier Function ◽

Anti Inflammatory

Ulcerative colitis is a type of chronic inflammation present in the intestines for which the aetiology is not yet clear. The current therapies for ulcerative colitis cannot be considered to be long-term management strategies due to their significant side effects. Therefore, it is essential to identify an alternative therapeutic strategy for ulcerative colitis. The present study focused on the evaluation of the anti-inflammatory activities of Lactobacillus acidophilus CGMCC 7282 and Clostridium butyricum CGMCC 7281. The roles of both single and combination of L. acidophilus CGMCC 7282 and C. butyricum CGMCC 7281 in ulcerative colitis were investigated in 2,4,6-trinitrobenzenesulfonic acid-induced acute colitis (Th1-type colitis) in Sprague-Dawley rats and oxazolone-induced chronic colitis (Th2-type colitis) in BALB/c mice. The in vivo studies showed that the administration of L. acidophilus CGMCC 7282, C. butyricum CGMCC 7281 and L. acidophilus CGMCC 7282 plus C. butyricum CGMCC 7281 could reduce the Th1-type colitis as well as the Th2-type colitis, and the combination of the two strains exhibited the most notable effects, as indicated by the reduced mortality rates, the suppressed disease activity indices, the improved body weights, the reduced colon weight/colon length and colon weight/body weight ratios, and the improved gross anatomic characteristics and histological features (ameliorations of neutrophil infiltration and ulceration in the colon). It was found that the alterations of the gut microbiome, the barrier function changing and the selected inflammation-related cytokines are observed in the ulcerative colitis rats/mice treated with L. acidophilus CGMCC 7282 and C. butyricum CGMCC 7281. The combination of L. acidophilus CGMCC 7282 plus C. butyricum CGMCC 7281 also exerted a stronger anti-inflammatory effect than either of the single strains alone in vitro. These findings provide evidence that the administration of L. acidophilus CGMCC 7282 plus C. butyricum CGMCC 7281 may be a promising therapy for ulcerative colitis.

Download Full-text